non-small cell lung cancer
Conditions
Interventions
Autologous Lymphocyte-Activated Killer cells (LAK) are injected on day0,day14,day28,day42,day56,day70. EGFR-TKI regulated dosage,regimen/day,oral daily.
Sponsors
Juntendo University, School of Medicine
Seta Clinic Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Non-small cell lung cancer patients who are judged SD or PD for EGFR-TKI therapy based on RECIST Patients who have measurable lesion -Performance Status is 0-1 -Life-expectancy is more than 4 months. -No serious abnormality in bone marrow, liver and/or renal functions
Exclusion criteria
Exclusion criteria: Patients who have: -Previous history of hypersensitivity to EGFR-TKI -Uncontrolled infections -Active autoimmune diseases -Serious cardiac disease -Continuous systemic administration of steroids. -Other cancer who are pregnant, to be pregnant, or nursing mothers, and whom principle investigator or co-investigator judged to be inappropriate to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Antitumor effect | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival Overall survival Survival rate Improvement of tumor-related markers QOL(FACT-BRM) Safety | — |
Countries
Japan
Contacts
Public ContactYoshiteru Morio
Juntendo University, School of Medicine Department of Respiratory Medicine
Outcome results
None listed